The Year 2011 is the Year of Melanoma: Melanoma Forum, Frankfurt, 19 May 2011

Česká verzia

Authors: J. Prošvicová; E. Kubala; J. Petera
Authors place of work: Klinika onkologie a radioterapie, LF UK a FN Hradec Králové
Published in the journal: Klin Onkol 2011; 24(4): 308-311
Category:

Zdroje

1. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008; 6: 62.

2. Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366(9492): 1189–1196.

3. Hansson J, Aamdal S, Bastholt L et al. Two different durations of adjuvant therapy with intermediate-dose interferon alpha-2b in patient with high-risk melanoma (Nordic IFN trial): a randomised phase III trial. Lancet Oncol 2011; 12(2): 144–152.

4. Vaňásková J, Grim J, Kopecký J et al. High-dose interferon alfa v léčbě pacientů s maligním melanomem, sledování prediktivních a prognostických biomarkerů. Klin Onkol 2011; 24(3): 180-186.

5. Ascierto PA, Kirkwood JM, Mozillo N et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010; 8: 76.

6. de La Salmonière P, Grob JJ, Dreno B et al. White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma. Clin Cancer Res 2000; 6(12): 4713–4718.

7. Kirkwood JM, Moschos SJ, Edington HD et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006; 24(19): 3164–3171.

8. Gogas H, Pectasides D, Kirkwood JM et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354(7): 709–718.

9. Eggermont AM, Bouwhuis MG, Suciu S et al. Autoimmune antibodies in recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101(12): 869–877.

10. Zeng G, Rosenberg SA, Robbins PF et al. Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 2002; 62(13): 3630–3635.

11. Hodi FS, Schadendorf D, Urba WJ et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711–723.

12. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9): 809–819.